Loading...

Aerie Pharmaceuticals

Nasdaq:AERI
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AERI
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. The last earnings update was 75 days ago. More info.


Add to Portfolio Compare Print
  • Aerie Pharmaceuticals has significant price volatility in the past 3 months.
AERI Share Price and Events
7 Day Returns
-8.4%
NasdaqGM:AERI
-0.9%
US Pharmaceuticals
-1.2%
US Market
1 Year Returns
-68.4%
NasdaqGM:AERI
3.7%
US Pharmaceuticals
3.4%
US Market
AERI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aerie Pharmaceuticals (AERI) -8.4% -25.2% -41.5% -68.4% 33.7% 24.8%
US Pharmaceuticals -0.9% -4.4% 0.6% 3.7% 0.2% 12.1%
US Market -1.2% 0.7% 1.7% 3.4% 35.5% 41.6%
1 Year Return vs Industry and Market
  • AERI underperformed the Pharmaceuticals industry which returned 3.7% over the past year.
  • AERI underperformed the Market in United States of America which returned 3.4% over the past year.
Price Volatility
AERI
Industry
5yr Volatility vs Market

AERI Value

 Is Aerie Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aerie Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aerie Pharmaceuticals.

NasdaqGM:AERI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.7%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:AERI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 21%) (1.61%))
0.827
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.827 * 5.96%)
7.66%

Discounted Cash Flow Calculation for NasdaqGM:AERI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Aerie Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:AERI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.66%)
2020 71.00 Analyst x2 65.95
2021 220.05 Analyst x2 189.86
2022 365.75 Analyst x2 293.11
2023 453.53 Analyst x3 337.61
2024 525.33 Est @ 15.83% 363.24
2025 587.85 Est @ 11.9% 377.55
2026 641.63 Est @ 9.15% 382.78
2027 687.98 Est @ 7.22% 381.24
2028 728.40 Est @ 5.88% 374.92
2029 764.32 Est @ 4.93% 365.43
Present value of next 10 years cash flows $3,131.70
NasdaqGM:AERI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $764.32 × (1 + 2.73%) ÷ (7.66% – 2.73%)
$15,932.41
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $15,932.41 ÷ (1 + 7.66%)10
$7,617.44
NasdaqGM:AERI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,131.70 + $7,617.44
$10,749.15
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,749.15 / 45.92
$234.1
NasdaqGM:AERI Discount to Share Price
Calculation Result
Value per share (USD) From above. $234.10
Current discount Discount to share price of $23.12
= -1 x ($23.12 - $234.10) / $234.10
90.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Aerie Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $23.12 vs Future cash flow value of $234.1
Current Discount Checks
For Aerie Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Aerie Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Aerie Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aerie Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aerie Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AERI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-5.53
NasdaqGM:AERI Share Price ** NasdaqGM (2019-07-19) in USD $23.12
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.84x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aerie Pharmaceuticals.

NasdaqGM:AERI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AERI Share Price ÷ EPS (both in USD)

= 23.12 ÷ -5.53

-4.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aerie Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Aerie Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Aerie Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:AERI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
61.9%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.7x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aerie Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aerie Pharmaceuticals's assets?
Raw Data
NasdaqGM:AERI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.18
NasdaqGM:AERI Share Price * NasdaqGM (2019-07-19) in USD $23.12
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 186 Publicly-Listed Pharmaceuticals Companies 3.1x
United States of America Market PB Ratio Median Figure of 5,247 Publicly-Listed Companies 1.79x
NasdaqGM:AERI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AERI Share Price ÷ Book Value per Share (both in USD)

= 23.12 ÷ 4.18

5.53x

* Primary Listing of Aerie Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aerie Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Aerie Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Aerie Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AERI Future Performance

 How is Aerie Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aerie Pharmaceuticals expected to grow at an attractive rate?
  • Aerie Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Aerie Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Aerie Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AERI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AERI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 61.9%
NasdaqGM:AERI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 44.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.2%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AERI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AERI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 725 481 7
2022-12-31 572 404 7
2021-12-31 408 295 7
2020-12-31 244 32 10
2019-12-31 101 -132 10
NasdaqGM:AERI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 35 -160 -240
2018-12-31 24 -153 -233
2018-09-30 10 -147 -240
2018-06-30 2 -125 -187
2018-03-31 -109 -160
2017-12-31 -93 -145
2017-09-30 -86 -116
2017-06-30 -86 -107
2017-03-31 -85 -102
2016-12-31 -80 -99
2016-09-30 -75 -90
2016-06-30 -66 -84

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aerie Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Aerie Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AERI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Aerie Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AERI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 6.12 6.49 5.75 2.00
2022-12-31 4.82 5.39 4.25 2.00
2021-12-31 2.23 3.46 1.00 2.00
2020-12-31 -0.64 0.60 -1.75 4.00
2019-12-31 -3.15 -2.56 -3.67 5.00
NasdaqGM:AERI Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -5.53
2018-12-31 -5.58
2018-09-30 -6.07
2018-06-30 -4.96
2018-03-31 -4.38
2017-12-31 -4.11
2017-09-30 -3.35
2017-06-30 -3.26
2017-03-31 -3.31
2016-12-31 -3.40
2016-09-30 -3.29
2016-06-30 -3.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aerie Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aerie Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aerie Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AERI Past Performance

  How has Aerie Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aerie Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aerie Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aerie Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aerie Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Aerie Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aerie Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AERI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 35.03 -239.82 133.97 91.04
2018-12-31 24.18 -232.57 120.61 86.12
2018-09-30 9.73 -239.62 129.86 97.73
2018-06-30 2.42 -186.61 109.70 81.64
2018-03-31 -160.02 65.36 74.10
2017-12-31 -145.11 56.91 72.08
2017-09-30 -115.91 66.07 48.07
2017-06-30 -107.36 56.92 48.35
2017-03-31 -102.14 49.15 51.04
2016-12-31 -99.06 34.71 52.39
2016-09-30 -90.11 37.46 50.60
2016-06-30 -84.26 34.30 47.82
2016-03-31 -79.83 32.41 45.14
2015-12-31 -74.36 30.64 44.45
2015-09-30 -70.49 29.37 41.74
2015-06-30 -65.67 26.85 40.07
2015-03-31 -58.70 24.51 36.12
2014-12-31 -48.13 20.10 29.87
2014-09-30 -41.95 17.32 23.43
2014-06-30 -39.69 15.66 17.60
2014-03-31 -34.34 12.43 14.10
2013-12-31 -31.60 10.29 11.88
2013-09-30 -25.08 8.01 10.70
2013-06-30 -17.92 6.14 9.67
2013-03-31 -15.51 5.34 9.46
2012-12-31 -15.64 5.02 9.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aerie Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aerie Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aerie Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aerie Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aerie Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AERI Health

 How is Aerie Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aerie Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aerie Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aerie Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aerie Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Aerie Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aerie Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:AERI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 192.15 0.00 148.87
2018-12-31 227.81 0.00 202.82
2018-09-30 268.58 0.00 235.95
2018-06-30 194.88 124.00 286.10
2018-03-31 236.27 123.92 333.98
2017-12-31 135.60 123.85 249.66
2017-09-30 159.27 123.77 281.33
2017-06-30 185.04 123.69 307.92
2017-03-31 84.12 123.62 207.86
2016-12-31 105.34 123.54 233.66
2016-09-30 128.36 123.46 253.63
2016-06-30 -17.40 123.39 107.03
2016-03-31 -0.16 123.31 119.29
2015-12-31 18.78 123.24 136.56
2015-09-30 32.48 124.25 155.24
2015-06-30 33.86 124.22 158.79
2015-03-31 48.62 124.19 169.74
2014-12-31 28.04 122.91 139.93
2014-09-30 42.16 124.13 171.06
2014-06-30 52.86 0.00 56.32
2014-03-31 62.27 0.00 65.11
2013-12-31 66.98 0.00 69.65
2013-09-30 -10.87 14.43 4.62
2013-06-30 8.72 0.00 9.88
2013-03-31 -0.57 2.33 2.93
2012-12-31 -0.57 2.33 2.93
  • Aerie Pharmaceuticals has no debt.
  • Aerie Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aerie Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Aerie Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 39.4% each year.
X
Financial health checks
We assess Aerie Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aerie Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AERI Dividends

 What is Aerie Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aerie Pharmaceuticals dividends.
If you bought $2,000 of Aerie Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aerie Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aerie Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AERI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AERI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aerie Pharmaceuticals has not reported any payouts.
  • Unable to verify if Aerie Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aerie Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aerie Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aerie Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aerie Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aerie Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AERI Management

 What is the CEO of Aerie Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vince Anido
COMPENSATION $6,774,726
AGE 66
TENURE AS CEO 6 years
CEO Bio

Dr. Vicente J. Anido, Jr., Ph.D., also known as Vince, has been the Chairman of Aerie Pharmaceuticals, Inc. since April 4, 2013 and its Chief Executive Officer since July 25, 2013. Dr. Anido is employed at Deltagen Inc. He served as the President and Chief Executive Officer of ISTA Pharmaceuticals Inc. since December 2001 to 2012. From June 2000 to September 2001, Dr. Anido served as a General Partner of Windamere Venture Partners LLC (Windamere Venture Partners) and Windamere Venture Partners II, L.P. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. He served as President/ General Manager of Nordic Laboratories in Montreal, Canada. He served as the President and Chief Executive Officer of Deltagen Research Laboratories, L.L.C. from March 1996 to 1999. Dr. Anido served as the President of the Americas Region at Allergan Inc., from June 1993 to 1996. He spent almost 18 years at Marion Laboratories Inc. and Marion Merrell Dow Inc. and served as Vice President of Business Management of its U.S. Prescription Products Division from 1991 to June 1993. He founded and serves as Chairman of MD Edge, Inc. He served as an Independent Director of QLT Inc. from July 9, 2012 to November 09, 2013. He served as an Independent Director of DepoMed Inc. from February 2013 to May 18, 2016. He served as a Director of ISTA Pharmaceuticals Inc., from 2001 to 2012 and Nicox SA from June 21, 2013 to August 6, 2014. He served as a Director of Apria Healthcare Group Inc. from 2002 to October 28, 2008. He served as a Director of FeRX Incorporated. He served as a Director of Deltagen Research Laboratories, L.L.C. from March 1996 to 1999. Dr. Anido holds a B.S. in Pharmacy from West Virginia University, an M.S. in Pharmaceutical Sciences from West Virginia University and a Ph.D. in Pharmacy Administration from the University of Missouri, Kansas City.

CEO Compensation
  • Vince's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Vince's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Aerie Pharmaceuticals management team in years:

1.4
Average Tenure
61
Average Age
  • The average tenure for the Aerie Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Vince Anido

TITLE
CEO & Chairman
COMPENSATION
$7M
AGE
66
TENURE
6 yrs

Tom Mitro

TITLE
President & COO
COMPENSATION
$3M
AGE
61
TENURE
5.9 yrs

Casey Kopczynski

TITLE
Co-Founder & Chief Scientific Officer
COMPENSATION
$2M
AGE
58
TENURE
14.5 yrs

Richard Rubino

TITLE
CFO, Secretary & Treasurer
COMPENSATION
$3M
AGE
61
TENURE
6.8 yrs

John LaRocca

TITLE
General Counsel & Assistant Secretary
COMPENSATION
$4M
AGE
54
TENURE
1.4 yrs

Jeffrey Calabrese

TITLE
Director of Accounting
TENURE
0.1 yrs

Ami Bavishi

TITLE
Director of Investor Relations
TENURE
0.5 yrs

Carmen Wasserman

TITLE
Chief Compliance Officer & Senior Corporate Counsel
TENURE
0.9 yrs

Tad Heitmann

TITLE
Head of Communications
TENURE
1.4 yrs

Kathleen McGinley

TITLE
Vice President of Human Resources & Corporate Services
AGE
69
Board of Directors Tenure

Average tenure and age of the Aerie Pharmaceuticals board of directors in years:

4.2
Average Tenure
66
Average Age
  • The tenure for the Aerie Pharmaceuticals board of directors is about average.
Board of Directors

Vince Anido

TITLE
CEO & Chairman
COMPENSATION
$7M
AGE
66
TENURE
6.3 yrs

Murray Goldberg

TITLE
Independent Director
COMPENSATION
$512K
AGE
74
TENURE
5.9 yrs

Jerry Cagle

TITLE
Independent Director
COMPENSATION
$509K
AGE
75
TENURE
5.8 yrs

Ben McGraw

TITLE
Lead Independent Director
COMPENSATION
$533K
AGE
70

Dave Gryska

TITLE
Director
COMPENSATION
$1M
AGE
64
TENURE
0.8 yrs

Rick Croarkin

TITLE
Independent Director
COMPENSATION
$502K
AGE
65
TENURE
4.2 yrs

Julie McHugh

TITLE
Independent Director
COMPENSATION
$507K
AGE
55
TENURE
4.1 yrs

Michael du Toit

TITLE
Independent Director
COMPENSATION
$504K
AGE
66
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
19. Nov 18 Buy Gerald Cagle Individual 16. Nov 18 16. Nov 18 2,000 $41.75 $83,493
14. Sep 18 Sell Richard Rubino Individual 13. Sep 18 13. Sep 18 -34,512 $60.17 $-2,076,608
06. Sep 18 Sell Casey Kopczynski Individual 04. Sep 18 04. Sep 18 -11,000 $61.00 $-661,024
02. Aug 18 Sell Casey Kopczynski Individual 01. Aug 18 01. Aug 18 -11,000 $68.69 $-751,298
X
Management checks
We assess Aerie Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aerie Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AERI News

Simply Wall St News

Should You Be Worried About Insider Transactions At Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)?

So shareholders might well want to know whether insiders have been buying or selling shares in Aerie Pharmaceuticals, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' See our latest analysis for Aerie Pharmaceuticals The Last 12 Months Of Insider Transactions At Aerie Pharmaceuticals In the last twelve months, the biggest single sale by an insider was when the CFO, Secretary & Treasurer, Richard Rubino, sold US$2.1m worth of shares at a price of US$60.17 per share. … Over the last year we saw more insider selling of Aerie Pharmaceuticals shares, than buying.

Simply Wall St -

Loss-Making Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected To Breakeven

Many investors are wondering the rate at which AERI will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for AERI, its year of breakeven and its implied growth rate. … Check out our latest analysis for Aerie Pharmaceuticals AERI is bordering on breakeven, according to the 11 Pharmaceuticals analysts. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Simply Wall St -

Announcing: Aerie Pharmaceuticals (NASDAQ:AERI) Stock Increased An Energizing 145% In The Last Five Years

Given that Aerie Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Simply Wall St -

Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Aerie Pharmaceuticals, Inc. … In the last twelve months, the biggest single sale by an insider was when CFO, Secretary & Treasurer Richard Rubino sold US$2.1m worth of shares at a price of US$60.17 per share. … All up, insiders sold more shares in Aerie Pharmaceuticals than they bought, over the last year.

Simply Wall St -

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Financial Strength Analysis

Today we will look at AERI’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Note that this information is centred entirely on financial health and is a top-level understanding, so I encourage you to look further. … Is AERI’s debt level acceptable?

Simply Wall St -

Should You Be Holding Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)?

(NASDAQ:AERI) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of AERI, it

Simply Wall St -

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Is Breakeven Near?

Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI):. … Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. … The US$1.6b market-cap posted a loss in its most recent financial year of -US$145.1m and a latest trailing-twelve-month loss of -US$239.6m leading to an even wider gap between loss and breakeven.

Simply Wall St -

Who Has Been Selling Aerie Pharmaceuticals Inc (NASDAQ:AERI) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Aerie Pharmaceuticals Inc (NASDAQ:AERI). … All up, insiders sold more shares in Aerie Pharmaceuticals than they bought, over the last year. … It is certainly not great to see that insiders have sold shares in the company

Simply Wall St -

How Does Aerie Pharmaceuticals Inc (NASDAQ:AERI) Affect Your Portfolio Volatility?

If you're interested in Aerie Pharmaceuticals Inc (NASDAQ:AERI), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

What does Aerie Pharmaceuticals Inc's (NASDAQ:AERI) Balance Sheet Tell Us About Its Future?

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Aerie Pharmaceuticals Inc (NASDAQ:AERI), with a market capitalization of US$3.02b, rarely draw their attention from the investing community. … AERI’s financial liquidity and debt position will be analysed in this article, to get an idea of whether the company can fund opportunities for strategic growth and maintain strength through economic downturns. … Check out our latest analysis for Aerie Pharmaceuticals

Simply Wall St -

AERI Company Info

Description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company’s advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Details
Name: Aerie Pharmaceuticals, Inc.
AERI
Exchange: NasdaqGM
Founded: 2005
$1,061,620,322
45,917,834
Website: http://www.aeriepharma.com
Address: Aerie Pharmaceuticals, Inc.
4301 Emperor Boulevard,
Suite 400,
Durham,
North Carolina, 27703,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AERI Common Stock Nasdaq Global Market US USD 25. Oct 2013
DB 0P0 Common Stock Deutsche Boerse AG DE EUR 25. Oct 2013
Number of employees
Current staff
Staff numbers
353
Aerie Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:07
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/19
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.